TargetMol

Ronifibrate

Product Code:
 
TAR-T28610
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T28610-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28610-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28610-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Ronifibrate is a lipid modifying agent with antihyperlipidemic and antiarteriosclerotic activity.
CAS:
42597-57-9
Formula:
C19H20ClNO5
Molecular Weight:
377.82
Purity:
0.98
SMILES:
CC(C)(Oc1ccc(Cl)cc1)C(=O)OCCCOC(=O)c1cccnc1

References

1. Carr JF, Lee HJ, Jaspers JB, Dahlberg AE, Jogl G, Gregory ST. Phenotypic Suppression of Streptomycin Resistance by Mutations in Multiple Components of the Translation Apparatus. J Bacteriol. 2015 Sep;197(18):2981-8. doi: 10.1128/JB.00219-15. Epub 2015 Jul 6. PubMed PMID: 26148717; PubMed Central PMCID: PMC4542173. 2. Labios M, Mart?nez M, Vay? A, Gabriel F, Guiral V, Aznar J. Effect of a modified fibrate (Biniwas Retard) on hemorheological alterations in hyperlipemic patients. Clin Hemorheol Microcirc. 1999;21(2):79-85. PubMed PMID: 10599590. 3. Corominas Vilardell A, de Oya Otero M, Escobar Jim?nez F, Anguera Vila A, Ari?o Armengol B. [Multicenter clinical, double blind, and randomized study to assess the effectiveness and safety of binifibrate versus gemfibrozil in type IIa, IIb, and IV hyperlipidemia]. An Med Interna. 1993 Nov;10(11):537-41. Spanish. PubMed PMID: 8117868. 4. Avellaneda A, Rueda A, Cascio C, Guti?rrez JA. [Changes in the lipid profiles of hyperlipemic patients treated with binifibrate]. An Med Interna. 1993 Jun;10(6):275-9. Spanish. PubMed PMID: 8334204.